IN BRIEF: Poolbeg Pharma shares soar on US patent grants

Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent ...

Alliance News 26 May, 2022 | 3:54PM
Email Form Facebook Twitter LinkedIn RSS

Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.

"Enhancing the IP protection of these assets across key markets such as the US increases the overall value of these products to potential partners, particularly as we move closer to the commencement of our POLB 001 LPS human challenge trial next month with data expected by year end and monetisation to commence thereafter," says Chief Executive Jeremy Skillington.

Current stock price: 7.54 pence, up 26% in London

12-month change: down 30%

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Poolbeg Pharma PLC Ordinary Shares 5.22 GBX -7.61 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.